Cocarnit Effects on Macrophages Polarization
Parole chiave
Astratto
Descrizione
Diabetes mellitus (DM) is the most common endocrine disease, and its social significance is associated with early disability and high mortality. Indicators of diabetes mellitus decompensation are its chronic complications, the most common one is a diabetic polyneuropathy. In recent years a large number of papers demonstrate the role of the chronic inflammatory process in the development of type 2 DM. Macrophages play a key role in the development of the inflammatory response. Macrophages are the main cells producing pro-inflammatory cytokines, which cause a cascade of reactions leading to the development of insulin resistance, that is the important factor of the pathogenesis of type 2 DM. There are two main types of activation of macrophages under the influence of T-helper cells 1 and 2. The first type is classical activation of macrophages that is a response to pro-inflammatory stimuli, such as interferon-gamma or lipopolysaccharide. Classically activated macrophages are well studied and characterized by the secretion of reactive oxygen species and pro-inflammatory cytokines such as TNF-alpha, interleukins 1,6,12. The second type is alternative activation of macrophages that is the result of the influence of anti-inflammatory cytokines, such as interleukins 4,10,13 or anti-inflammatory mediators, for example, glucocorticoids. The result of alternative activation of macrophages is the expression of anti-inflammatory cytokines such as antagonist receptor interleukin 1, interleukin 10, CCL18, haptoglobin receptor CD163, scavenger receptor type1.
Cocarnit is a metabolic complex containing disodium adenosine triphosphate trihydrate 10mg, cocarboxylase 50mg, cyanocobalamin 500mg and nicotinamide 20mg.
The aim of the present study is to test the effects of Cocarnit on pro- and anti-inflammatory activation of blood-derived monocytes-macrophages from Type 2 diabetic patients.
The profile of monocyte polarization was determined in vitro in primary cell culture of blood-derived monocytes-macrophages after pro-inflammatory stimulation by bacterial lipopolysaccharide and after anti-inflammatory stimulation by interleukin-4, according to tumor necrosis factor (TNF) and CCL18 chemokine secretion, respectively.
Study design: Open label study included 40 Type 2 diabetic patients divided into two groups:
1. Newly-diagnosed type-2 DM - 20 participants;
2. Type-2 DM with polyneuropathy - 20 participants.
The following measurements are held:
1. stimulated and basal secretion of TNF-alpha before and at 2 and 4 hours after single intramuscular administration of Cocarnit at first day and 30 days of follow-up.
2. stimulated and basal secretion of CCl-18 before and at 2 and 4 hours after single intramuscular administration of Cocarnit at first day and after 30 days of follow-up.
The research database is compiled upon completion of the study and then a statistical analysis of the results is carried out.
Date
| Ultimo verificato: | 02/28/2019 |
| Primo inviato: | 03/10/2019 |
| Iscrizione stimata inviata: | 03/13/2019 |
| Primo pubblicato: | 03/14/2019 |
| Ultimo aggiornamento inviato: | 03/18/2019 |
| Ultimo aggiornamento pubblicato: | 03/20/2019 |
| Data di inizio effettiva dello studio: | 10/02/2018 |
| Data di completamento primaria stimata: | 11/17/2018 |
| Data stimata di completamento dello studio: | 12/19/2018 |
Condizione o malattia
Intervento / trattamento
Dietary Supplement: Cocarnit
Fase
Gruppi di braccia
| Braccio | Intervento / trattamento |
|---|---|
| Experimental: Cocarnit disodium adenosine triphosphate trihydrate 10mg, cocarboxylase 50mg, cyanocobalamin 500mg and nicotinamide 20mg | Dietary Supplement: Cocarnit a metabolic complex |
Criteri di idoneità
| Sessi idonei allo studio | All |
| Accetta volontari sani | sì |
| Criteri | Inclusion Criteria: 1. Type 2 diabetes mellitus newly-diagnosed (for group 1) 2. Type 2 diabetes and diabetic polyneuropathy (for group 2) 3. Availability of informed consent to participate in the study Exclusion Criteria: 1. Refusal to sign informed consent to participate in the study 2. Presence of chronic diseases that require constant medication, except preparations for the correction of diabetes 3. Individual intolerance to the preparation 4. Infectious disease or fever during the period of inclusion 5. Refusal to take the preparation during the study 6. Non-compliance with inclusion criteria |
Risultato
Misure di esito primarie
1. Change in macrophages activation after single Cocarnit administration [4 hours]
2. Change in macrophages activation after 30-days Cocarnit administration [30 days]
